Rivulet Media Inc (fka RIVU)

[PG]

As it has been conveyed by Bio-Matrix Scientific Group from the very start--as with so many aspects of the treatments they are in the process of harnessing, their approach is NOVEL. In short, they are doing things that have never been done. And in doing so, they are setting themselves up to take a market that has so long been dictated one way, and showing that is CAN be done quite successfully in another.

A way that will prove beneficial to all those with and without a vested interest.

HemaXellerate I™ is a patient-specific composition of cells that have previously been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies. The company, together with an internationally-renowned group of stem cell researchers, recently published the scientific basis for the HemaXellerate I™ product.

If the clinical trial is successful, the company plans to expand use of HemaXellerate I™ to other conditions associated with bone marrow dysfunction, with the overall goal of entering the hematopoietic growth factor market. This market is substantial in size and currently includes drugs such as Neupogen®, Neulasta®, Leukine® and Revolade®.

"Current drug-based approaches for healing bone marrow damage involve "flooding" the body with growth factors, which is extremely expensive and causes unintended consequences because of lack of selectivity," said Dr. Vladimir Bogin, CEO of Chromos Pharma (a contract research organization), which collaborated with Regen on filing the IND and member of the Company's Scientific Advisory Board. "Based on our data HemaXellerate I™ possesses the advantage delivering an optimized cellular mixture that produces the needed growth factors at the specific location in the bone marrow niche."

HemaXellerate is a derivative of HemXellerate--an offshoot or scion. There are a vast number of illnesses that could be treated by the HemXellerate approach of cell proliferation. This science, the science of stem cell treatment, which has been frowned upon by so many due to a lack of understanding and education, has been studied for more than forty years. Many things have been done to thwart the efforts of scientists in the past. However, due to the ever increasing changes in the approach itself (i.e., methods for extracting the cells) coupled with heightened awareness and demand, the time where this type of treatment will be preferable to any treatment that exposes a patient to toxins, stem cell treatment will be demanded by patients/consumers/governments in a pharmaceutical market that is expected to reach 1.1 trillion dollars by 2015.

GO BMSN!

---